Workflow
Opella
icon
Search documents
VIRBAC: Paul Martingell is appointed chief executive officer of Virbac, effective September 1, 2025
Globenewswire· 2025-06-19 06:30
Core Viewpoint - Virbac has appointed Paul Martingell as the new CEO, effective September 1, 2025, bringing extensive international experience in consumer health and pharmaceuticals to the role [1][5]. Group 1: Leadership and Experience - Paul Martingell, aged 45, has over 25 years of international experience, particularly in consumer health, consumer goods, and pharmaceuticals [1][2]. - His previous roles include significant positions at Ernst & Young, Reckitt Benckiser, and Novartis Consumer Healthcare, where he was part of the executive committee overseeing the merger of Boehringer Ingelheim's and Sanofi's Consumer Healthcare businesses [2][3]. - Martingell has demonstrated leadership in developing diverse teams and leading successful transformations, focusing on growth and performance [3]. Group 2: Strategic Vision - Martingell expressed enthusiasm for joining Virbac and aims to innovate and create a lasting impact in the animal health sector [4]. - The board of directors believes that his background and leadership style will contribute to the long-term development of Virbac by providing a new perspective [5]. Group 3: Transition and Acknowledgment - The board of directors acknowledged the contributions of Habib Ramdani, who served as interim CEO prior to Martingell's appointment [6].
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
Globenewswire· 2025-04-30 11:00
Company Overview - Sanofi has completed the sale of a 50.0% controlling stake in its consumer healthcare business, Opella, to CD&R, while retaining a 48.2% stake [1] - The transaction generated approximately €10 billion in net cash proceeds for Sanofi [1] Opella's Position and Strategy - Opella is now an independent global leader in consumer healthcare, positioned for long-term success with a strong brand portfolio and international reach [3][5] - The company employs over 11,000 people and operates in 100 countries, with 13 manufacturing sites and four development centers [5] - Opella is the third-largest player in the OTC and vitamins, minerals & supplements market, serving over half a billion consumers globally [5] Future Outlook - CD&R aims to support Opella in becoming a global consumer health champion, leveraging its expertise in the consumer health sector [4] - Opella is focused on unlocking its full potential and driving value creation through innovation and exceptional talent [5]